SAN DIEGO, Oct. 3 /PRNewswire-FirstCall/ -- Accelrys Inc., a wholly owned subsidiary of Pharmacopeia, Inc. (Nasdaq: PCOP), today announced the introduction of its latest Discovery Studio(TM) release: Discovery Studio SeqStore. Scheduled for commercial availability in October 2002, DS SeqStore is a complete, Oracle(R) based enterprise solution for managing, analyzing, and visualizing genomic and proteomic sequence data. Designed to meet the needs of biologists, bioinformaticians, and database administrators, DS SeqStore provides robust and flexible data management capabilities, a secure environment for research and collaboration, up-to-date sequence data, and seamless integration with the GCG(R) Wisconsin Package(R). DS SeqStore enables life science research organizations to effectively utilize the vast volumes of genomic and proteomic sequence data available today. It delivers a unified environment for managing public, proprietary and third-party data that can be integrated with proprietary and third-party analysis applications. As such, the solution provides a single point of access for all of an organization's research data, analysis and visualization tools. DS SeqStore represents the latest addition to the Discovery Studio family of products and furthers Accelrys' strategy of providing comprehensive and integrated bioinformatics and proteomics solutions. DS SeqStore complements DS Gene, Accelrys' first Discovery Studio bioinformatics product, and provides powerful scientific tools with comprehensive knowledge management capabilities to enable knowledge transfer across the enterprise. Within DS SeqStore users can register new sequences, record analysis results, annotate existing sequences as new discoveries are made, and integrate and manage data from multiple sources in multiple formats. Users can also save multiple versions of sequences and annotations, enhancing collaboration and recording discovery histories for patent purposes. DS SeqStore automatically updates the database as new information becomes available, giving researchers across the organization access to the most current data. DS SeqStore will be demonstrated at the Genome Sequencing and Analysis Conference (GSAC) in Boston this week. Please visit us there in Booth # 317. Discovery Studio Discovery Studio is a powerful research environment for the life sciences that delivers a comprehensive suite of informatics, modeling, and simulation solutions. This enterprise-wide family of products is composed of a wide breadth of tools, client-server applications, and databases for handling the specific research problems encountered by scientists working in the discovery process. The Discovery Studio design enables collaboration across scientific disciplines through a centralized project and knowledge management system, connecting the research conducted by biologists and chemists. In addition, Discovery Studio is an open platform built on industry-standard components so that it can leverage existing IT infrastructure and the integration of third-party applications, public domain, and other in-house developed applications. About Accelrys Inc. Accelrys is a leading provider of software for computation, simulation, and the management and mining of scientific data used by biologists, chemists, and materials scientists for product design, drug discovery, and development. Accelrys' platform technology and consulting services enable enterprise-wide solutions tailored to today's leading research organizations. The company's two main centers of excellence are in San Diego, and Cambridge, UK. These centers combine research and product development with facilities to support significant collaborative projects. Accelrys is a subsidiary of Pharmacopeia, Inc. (Nasdaq: PCOP) and was launched in June 2001, combining leading software companies Molecular Simulations Inc., Synopsys Scientific Systems, Oxford Molecular, GCG, and Synomics Ltd. More information on Accelrys can be found at http://www.accelrys.com. Discovery Studio is a registered trademark of Accelrys Inc. within the United States and/or various other countries. When used anywhere in this document, the words expects, believes, anticipates, estimates, and similar expressions are intended to identify forward-looking statements. Forward-looking statements herein may include statements addressing future financial and operating results of Pharmacopeia. Pharmacopeia has based these forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of Pharmacopeia's strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of existing and potential future patent issues, additional competition, changes in economic conditions, and other risks described in documents Pharmacopeia has filed with the Securities and Exchange Commission, including its most recent report on Form 10-K and subsequent reports on Form 10-Q. All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Pharmacopeia disclaims any undertaking to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. Contact: Jim Rivas Accelrys 1-858-799-5393 email@example.com MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X15778686
SOURCE Accelrys, Inc.